Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer

Tianjin Medical University Cancer Institute and Hospital80 enrolled

Overview

Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma Breast Stage IV

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients must be the postmenopausal women 2. Patients must be diagnosed with advanced breast cancer by imageology，cytology or histopathology 3. Immunohistochemistry shows ER and/or PR positive 4. Patients ECOG score must be 0-2 5. Drug resistant about Non-Steroid Aromatase Inhibitors Exclusion Criteria: 1. Not suitable for endocrine therapy 2. Have receive the standard Steroid Aromatase Inhibitors treatment 3. Severe hepatic dysfunction

Locations (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

RECRUITING

Outcomes

Primary Outcomes

RECIST 1.1

Time frame: -7 days

Central Contacts

Yehui Shi, MD

CONTACT

022-23340123-1052 shiyehui@tom.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.